Compare AUID & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | BOLT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.7M |
| IPO Year | 2014 | 2021 |
| Metric | AUID | BOLT |
|---|---|---|
| Price | $0.31 | $12.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 387.3K | 20.3K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,040,660.00 | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,525.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.20 | 0.07 |
| 52 Week Low | $0.30 | $3.10 |
| 52 Week High | $2.87 | $7.20 |
| Indicator | AUID | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 80.15 |
| Support Level | N/A | $3.53 |
| Resistance Level | $0.59 | $7.16 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 7.97 | 68.40 |
AuthID Inc is a company engaged in ensuring enterprises - Know Who's Behind the Device, for every customer or employee login and transaction, through its easy-to-integrate, patented, biometric identity platform. authID powers biometric identity proofing, biometric authentication, and account recovery with a fast, accurate, user-friendly experience. With its PrivacyKey solution, authID provides accurate biometric authentication while storing no biometric data. authID's goal is to stop fraud at onboarding, blocks deepfakes, prevents account takeover, and eliminates password risks and costs, through the faster, and accurate user identity experience demanded by the digital ecosystem Its products are: IDX Mandate for Agentic AI, PrivacyKey, Identity Verification, and Biometric Authentication.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.